Matinas BioPharma receives notice from NYSE

* Matinas BioPharma (NYSE: MTNB [https://seekingalpha.com/symbol/MTNB]) said [https://seekingalpha.com/pr/20462304-matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing] on Friday it received a notice from NYSE American on April 2, 2026, for non-compliance with Section 1003(a)(i) listing standard.
* NYSE American said the company failed to meet stockholders’ equity requirements under Sections 1003(a)(i)-(iii), which mandate minimum equity of $2M, $4M, or $6M depending on recent loss history.
* The notice said the company had stockholders’ equity of $4.83M as of Dec. 31, 2025, with losses over the past five fiscal years, making it ineligible for any exemption under Section 1003(a).
* The company is now subject to Section 1009 procedures and has until May 2, 2026, to submit a compliance plan, with up to 18 months from the notice date to regain compliance.

MORE ON MATINAS BIOPHARMA

* Financial information for Matinas Biopharma [https://seekingalpha.com/symbol/MTNB/income-statement]